Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44) : a randomised phase 3 trial.

Untch, Michael; Loibl, Sibylle; Kühn, Thorsten

dc.contributor.author	Kühn, Thorsten
dc.date.accessioned	2016-01-21T13:24:56Z
dc.date.available	2016-01-21T13:24:56Z
dc.date.issued	2012
dc.identifier.issn	1470-2045
dc.identifier.uri	http://hdl.handle.net/10900/67805
dc.language.iso	en	de_DE
dc.publisher	Oxford : Elsevier	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/S1470-2045(11)70397-7	de_DE
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.ddc	610	de_DE
dc.title	Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44) : a randomised phase 3 trial.	de_DE
dc.type	Article	de_DE
utue.publikation.seiten	135-144	de_DE
utue.personen.roh	Untch, Michael
utue.personen.roh	Loibl, Sibylle
utue.personen.roh	Kühn, Thorsten
dcterms.isPartOf.ZSTitelID	Lancet Oncology	de_DE
dcterms.isPartOf.ZS-Issue	2	de_DE
dcterms.isPartOf.ZS-Volume	13	de_DE